0.84

2.22% -0.0191

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.84, with a volume of 55,374. It is down -2.22% in the last 24 hours and down -25.00% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Previous Close:

$0.8591

Open:

$0.84

24h Volume:

55,374

Relative Volume:

0.01

Market Cap:

$19.40M

Revenue:

Net Income/Loss:

$-16.28M

P/E Ratio:

-0.0604

EPS:

-13.91

Net Cash Flow:

$-13.75M

1W Performance:

-9.42%

1M Performance:

-25.00%

6M Performance:

+15.70%

1Y Performance:

-66.67%

1-Day Range:

$0.8319

$0.86

1-Week Range:

$0.8319

$0.9183

52-Week Range:

$0.281

$3.85

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2024-08-11

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.84	19.84M	0	-16.28M	-13.75M	-13.91
VRTX Vertex Pharmaceuticals Inc	473.06	120.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	768.47	80.15B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	865.89	51.56B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	358.81	47.74B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	336.12	37.38B	4.98B	69.59M	525.67M	0.5197

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Jan 25, 2026

Performance Recap: Should I average down on WRAP stockMarket Movers & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Jan 25, 2026

Aug Shorts: Can Pasithea Therapeutics Corp sustain earnings growth2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Jan 25, 2026

Jan 24, 2026

How does SWVL compare to its peersEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn

Jan 24, 2026

Jan 22, 2026

Published on: 2026-01-22 13:20:30 - baoquankhu1.vn

Jan 22, 2026

Jan 16, 2026

Aug Big Picture: Is Finward Bancorp benefiting from interest rate changes2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 16, 2026

Jan 15, 2026

Pasithea Therapeutics regains Nasdaq compliance - MSN

Jan 15, 2026

Jan 14, 2026

New Highs: Can Pasithea Therapeutics Corp grow without external fundingJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - baoquankhu1.vn

Jan 14, 2026

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway - TipRanks

Jan 14, 2026

Pasithea provides updates on clinical trials for MEK inhibitor drug By Investing.com - Investing.com Canada

Jan 14, 2026

Jan 13, 2026

Pasithea provides updates on clinical trials for MEK inhibitor drug - Investing.com

Jan 13, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network

Jan 13, 2026

Pasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced Cancer - Quiver Quantitative

Jan 13, 2026

Jan 12, 2026

Risk Hedge: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesMarket Growth Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 12, 2026

Jan 10, 2026